Concepedia

Pharmacokinetic Characterization of Different Dose Combinations of Coadministered Tipranavir and Ritonavir in Healthy Volunteers

Thomas R. MacGregor, John P. Sabo, Stephen H. Norris, Philip A. Johnson, Lawrence Galitz, Scott McCallister

HIV Clinical Trials · 2004 · 64 citations · 13 references

DOI

Abstract

This phase 1 study demonstrated that RTV-boosted TPV achieves concentrations that are expected to be effective in treating drug-experienced patients.

References

13

Antiretroviral-Drug Resistance among Patients Recently Infected with HIV

Susan J. Little, Sarah Holte, Jean‐Pierre Routy et al. · New England Journal of Medicine · 2002 · 1.1K citations · Full text

Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients.

Paul B. Watkins, Scott A Murray, L G Winkelman et al. · Journal of Clinical Investigation · 1989 · 351 citations · Full text

, , +20

Tipranavir (PNU-140690):  A Potent, Orally Bioavailable Nonpeptidic HIV Protease Inhibitor of the 5,6-Dihydro-4-hydroxy-2-pyrone Sulfonamide Class

Steve R. Turner, Joseph W. Strohbach, Rubén Tommasi et al. · Journal of Medicinal Chemistry · 1998 · 293 citations · Full text

Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir.

T. Koudriakova, Eugenia Iatsimirskaia, Ilya Utkin et al. · PubMed · 1998 · 243 citations

, , +18

Potent Inhibition of the Cytochrome P-450 3A-Mediated Human Liver Microsomal Metabolism of a Novel HIV Protease Inhibitor by Ritonavir: A Positive Drug-Drug Interaction

Gondi Kumar, J.C. Dykstra, Ellen Roberts et al. · Drug Metabolism and Disposition · 1999 · 166 citations